Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

Abstract

Abstract Background Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%. Methods This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant. Results Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program. Conclusions Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.

Keywords

• Pneumococcal conjugate vaccine
• Catch-up vaccination
• Pneumococcal
• PCV13
• 13-valent